Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review

IntroductionIdiopathic Parkinson syndrome (iPS) is one of the most common neurodegenerative disorders characterised by the triad of bradykinesia, rigidity and tremor. Tremor at rest predominantly at one side is often perceived by patients as severely disabling and yet ranges among the most difficult symptoms to treat. In medically refractory cases, lesional approaches have proven to be effective alternatives. However, to date, there is no comprehensive analysis of non-surgical therapies to manage iPS-patients’ tremor. We therefore present a detailed study protocol for a systematic literature review assessing efficacy/effectiveness and safety of non-lesional treatments for tremor in iPS.Methods and analysisWe will search three electronic databases (MEDLINE, EMBASE and PsycINFO) using a combination of title/abstract keywords. Additionally, hand-searched reference and citation lists of key reviews identified through the search strategy will be screened. Eligible studies should investigate the efficacy/effectiveness and safety of therapeutic options for tremor in iPS excluding lesional interventions. Publications will be independently assessed for inclusion criteria by two investigators and study information summarised using a standardised template including quality assessment according to the QualSyst tool. We will provide a narrative synthesis of results and conduct a meta-analysis whenever possible.Ethics and disseminationWe commit to present contemporary evidence on the efficacy/effectiveness and safety of non-lesional interventions for tremor in iPS in a future publication. We aim to compile rich data of published studies to inform healthcare professionals in order to ultimately improve patient outcomes.PROSPERO registration numberCRD42020202911).

Download Full-text

Systematic Literature Review of Real-World Evidence of C Eftolozane/Tazobactam for the Treatment of Respiratory Infections

10.21203/rs.3.rs-415191/v1 ◽

2021 ◽

Author(s):

Laura Puzniak ◽

Ryan Dillon ◽

Thomas Palmer ◽

Hannah Collings ◽

Ashley Enstone

Keyword(s):

Clinical Trials ◽

Literature Review ◽

Systematic Literature Review ◽

Real World ◽

Bacterial Pneumonia ◽

Respiratory Infections ◽

Clinical Success ◽

Multidrug Resistant ◽

Success Rates ◽

Gram Negative

Abstract Background: Gram-negative nosocomial pneumonia (NP), including hospital-acquired bacterial pneumonia (HABP), ventilated HABP (vHABP), and ventilator-associated bacterial pneumonia (VABP), is a significant cause of morbidity and mortality. Common pathogens, including Enterobacterales and Pseudomonas aeruginosa are highly prevalent in healthcare settings and have few effective treatment options due to high rates of antibacterial resistance. Resistant pathogens are associated with significantly worse outcomes and higher costs, relative to patients with susceptible infections. Ceftolozane/tazobactam (C/T) has established efficacy in clinical trials of patients with NP. This review aimed to collate data on C/T use for HABP/vHABP/VABP infections in real-world clinical practice. Methods: This systematic literature review searched online biomedical databases for real-world studies of C/T for gram-negative respiratory tract infections (RTIs) up to June 2020. Relevant study, patient, and treatment characteristics, microbiology, and efficacy outcomes were captured.Results: Thirty-three studies comprising 658 patients were identified. Pneumonia was the most common infection C/T was used to treat (85%), with a smaller number of unspecified RTIs (9%) and tracheobronchitis (5%) reported. Data on severity of illness and comorbidity were inconsistently reported. The majority of patients had respiratory infections caused by P. aeruginosa (92.8%), of which 88.1% were multidrug-resistant (including extensively drug-resistant or pandrug-resistant). Examination of these studies demonstrated an increase in the percentage of patients receiving the recommended dose of C/T for respiratory infections (3 g q8h or renal impairment-adjusted) over time (36.8% of patients in 2017 to 71.5% in 2020). Clinical success rates ranged from 51.4–100%, with 10 studies (55.6% of studies reporting clinical success) reporting clinical success rates of >70%; microbiological success rates ranged from 57.0–100.0%, with three studies (60.0% of studies reporting microbiological success) reporting microbiological success rates of >70%. Thirty-day mortality ranged from 0.0–33.0%, with nine studies (90% of studies reporting mortality) reporting 30-day mortality of <30%. Conclusions: The studies identified in this review demonstrate that C/T shows similar outcomes as those seen in clinical trials, despite the higher frequency of multidrug-resistant pathogens, and comorbidities/conditions that may have been excluded from the trials.

Download Full-text

PSY13 - THE TREATMENT OPTIONS FOR ACUTE ATTACK OF HEREDITARY ANGIOEDEMA (HAE): A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS

Value in Health ◽

10.1016/j.jval.2018.09.2590 ◽

2018 ◽

Vol 21 ◽

pp. S438

Author(s):

J. Cho ◽

S. Jang ◽

D. An ◽

E. Lee ◽

H. Kim

Keyword(s):

Literature Review ◽

Systematic Literature Review ◽

Hereditary Angioedema ◽

Meta Analysis ◽

Treatment Options ◽

Acute Attack

Download Full-text

An Insight into Peri-Implantitis: A Systematic Literature Review

Primary Dental Journal ◽

10.1308/205016813806144209 ◽

2013 ◽

Vol 2 (2) ◽

pp. 69-73 ◽

Cited By ~ 14

Author(s):

Victoria Wilson

Keyword(s):

Literature Review ◽

Periodontal Disease ◽

Systematic Literature Review ◽

Oral Hygiene ◽

English Language ◽

Treatment Options ◽

Signs And Symptoms ◽

Radiographic Findings ◽

Implant Surgery ◽

Definition Of

Aim This systematic literature review was performed to establish a definition of peri-implantitis, what makes a patient more susceptible to peri-implantitis, the signs and symptoms of peri-implantitis (including radiographic findings), treatment options for peri-implantitis, and to investigate what constitutes a suitable oral hygiene regime. Method A systematic literature review and analysis of publications included in PubMed (articles published between 1998 and 2003; English language; search terms “peri-implantitis”; “mucositis”; “partially edentulous”; “preventative maintenance”; “peri-implantitis and plaque control”; “tissue augmentation”; “diet maintenance of peri-implantitis”; “oral hygiene instruction for implants”) was performed to identify papers providing information about peri-implantitis. Separately sourced publications with peri-implantitis related titles and abstracts were reviewed and analysed. The set criteria for inclusion were peer-reviewed articles. Of 53 papers identified, 23 were included for systematic review. Results Analysis of the papers revealed that patients with implants are more susceptible to developing peri-implantitis than are patients with natural teeth to developing periodontal disease. This is due to the varied peri-implant tissue that surrounds the implant in comparison with the tissue that surrounds a natural tooth. If active periodontal disease is present, peri-implantitis may also develop; however, other secondary factors may also need to be present for this to occur. Conclusion A comprehensive periodontal examination should be carried out prior to implant surgery. The patient should be informed of the necessity of regular maintenance following implant surgery and the prerequisite of maintaining a comprehensive oral hygiene regime to avoid peri-implantitis.

Download Full-text

Comparative efficacy and safety of dabrafenib in combination with trametinib versus competing adjuvant therapies for high-risk melanoma

Journal of Comparative Effectiveness Research ◽

10.2217/cer-2019-0061 ◽

2019 ◽

Vol 8 (16) ◽

pp. 1349-1363 ◽

Cited By ~ 2

Author(s):

Rohini Sharma ◽

Roy Koruth ◽

Steve Kanters ◽

Eric Druyts ◽

Ahmad Tarhini

Keyword(s):

High Risk ◽

Literature Review ◽

Systematic Literature Review ◽

Distant Metastasis ◽

Checkpoint Inhibitors ◽

Treatment Options ◽

Comparable Efficacy ◽

Relapse Free Survival ◽

Free Survival ◽

Distant Metastasis Free Survival

Aim To conduct a systematic literature review of high-risk resectable cutaneous melanoma adjuvant therapeutics and compare safety and efficacy. Methods: The systematic literature review included randomized controlled trials investigating: dabrafenib plus trametinib (DAB + TRAM), nivolumab, pembrolizumab, ipilimumab, vemurafenib, chemotherapy and interferons. Outcomes included overall survival (OS), relapse-free survival, distant metastasis-free survival and safety. All outcomes were synthesized using Bayesian network meta-analysis. Results: Across relapse-free survival, distant metastasis-free survival and OS, DAB + TRAM had the lowest estimated hazards of respective events relative to all other treatments (exception relative to nivolumab in OS). Differences were significant relative to placebo, chemotherapy, interferons and ipilimumab. Conclusion: DAB + TRAM has improved efficacy over historical treatment options (ipilimumab, interferons and chemotherapy) and comparable efficacy with other targeted and immune checkpoint inhibitors.

Download Full-text

Real-world use of ceftolozane/tazobactam: a systematic literature review

Antimicrobial Resistance and Infection Control ◽

10.1186/s13756-021-00933-8 ◽

2021 ◽

Vol 10 (1) ◽

Author(s):

Laura Puzniak ◽

Ryan Dillon ◽

Thomas Palmer ◽

Hannah Collings ◽

Ashley Enstone

Keyword(s):

Clinical Practice ◽

Literature Review ◽

Systematic Literature Review ◽

Real World ◽

Comparative Studies ◽

Clinical Success ◽

Mortality Rates ◽

Success Rates ◽

Gram Negative ◽

Seriously Ill

Abstract Background Antibacterial-resistant gram-negative infections are a serious risk to global public health. Resistant Enterobacterales and Pseudomonas aeruginosa are highly prevalent, particularly in healthcare settings, and there are limited effective treatment options. Patients with infections caused by resistant pathogens have considerably worse outcomes, and incur significantly higher costs, relative to patients with susceptible infections. Ceftolozane/tazobactam (C/T) has established efficacy in clinical trials. This review aimed to collate data on C/T use in clinical practice. Methods This systematic literature review searched online biomedical databases for real-world studies of C/T for gram-negative infections up to June 2020. Relevant study, patient, and treatment characteristics, microbiology, and efficacy outcomes were captured. Results There were 83 studies comprising 3,701 patients were identified. The most common infections were respiratory infections (52.9% of reported infections), urinary tract infections (UTIs; 14.9%), and intra-abdominal infections (IAIs; 10.1%). Most patients included were seriously ill and had multiple comorbidities. The majority of patients had infections caused by P.aeruginosa (90.7%), of which 86.0% were antimicrobial-resistant. C/T was used as both a 1.5 g q8h and 3 g q8h dose, for a median duration of 7–56 days (varying between studies). Outcome rates were comparable between studies: clinical success rates ranged from 45.7 to 100.0%, with 27 studies (69%) reporting clinical success rates of > 70%; microbiological success rates ranged from 31 to 100%, with 14 studies (74%) reporting microbiological success rates of > 70%. Mortality rates ranged from 0 to 50%, with 31 studies (69%) reporting mortality rates of ≤ 20%. In comparative studies, C/T was as effective as aminoglycoside- or polymyxin-based regimens, and in some instances, significantly more effective. Conclusions The studies identified in this review demonstrate that C/T is effective in clinical practice, despite the diverse group of seriously ill patients, different levels of resistance of the pathogens treated, and varying dosing regimens used. Furthermore, comparative studies suggest that C/T offers a successful alternative to standard of care (SoC).

Download Full-text